The Beneluxa Initiative welcomes the new EU Health Technology Assessment Regulation, in full effect as of 12th January 2025. The phased implementation will include comparative effectiveness assessment for cancer medicines and advanced therapeutic medicinal products as well as joint scientific consultations for all medicines.
Member States of the Beneluxa initiative have played key roles in supporting its introduction. The Initiative will work to incorporate the joint assessments into joint work on pricing and reimbursement. Leveraging the benefits of European collaboration is an important strategic issue for the Beneluxa initiative.
Find more information on this topic on the webpage of the European Commission: https://health.ec.europa.eu/health-technology-assessment/implementation-regulation-health-technology-assessment_en